Envista Holdings Corp
$ 29.43
1.55%
24 Feb - close price
- Market Cap 4,765,072,000 USD
- Current Price $ 29.43
- High / Low $ 29.64 / 28.96
- Stock P/E 103.50
- Book Value 18.96
- EPS 0.28
- Next Earning Report 2026-04-30
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.03 %
- ROE 0.02 %
- 52 Week High 30.42
- 52 Week Low 14.22
About
Envista Holdings Corporation, develops, manufactures and markets dental products in the United States and internationally. The company is headquartered in Brea, California.
Analyst Target Price
$28.46
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-30 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.31 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: NVST
2026-02-16 07:27:26
This article advises investors to avoid Envista Holdings Corp (NVST) despite its recent stock performance. The author highlights three main reasons: disappointing long-term revenue growth, previous growth initiatives losing money due to negative ROIC, and a decline in new investment returns. Instead, the article suggests looking into the most entrenched endpoint security platform on the market and provides a link to "Top 6 Stocks" list.
2026-02-13 09:23:00
Envista Holdings Corporation (NVST) reported strong Q4 2025 results, with adjusted EPS up 58.3% year over year and revenues increasing by 15%, both beating Zacks Consensus Estimates. Despite a contraction in gross margin, the company's operational profit significantly improved, and its shares rallied post-announcement. Envista remains optimistic about its core sales growth and adjusted EBITDA margins for 2026, benefiting from its diverse portfolio in specialty products and technologies.
2026-02-12 09:57:16
Envista Holdings (NVST) reported stronger-than-anticipated Q4 results with significant revenue and profit growth, driven by new product launches and increased customer training. This article highlights five key analyst questions from the earnings call, covering topics such as 2026 guidance risks and upsides, drivers for Q4 growth, new product contributions to implant growth, Spark's profitability, and SG&A leverage and R&D investment. The company's future catalysts include new product commercial impact, Spark's operational efficiency, and developments in China's VBP policy.
2026-02-11 23:57:43
Envista Holdings Corporation's SVP, Mischa Reis, sold 9,675 shares of company stock for approximately $290,250 on February 10th, reducing their holdings by 23%. This insider sale comes as Envista's stock trades near its 52-week high with a high P/E ratio, despite strong Q4 earnings, positive guidance, and analyst upgrades. Investors are advised to consider this insider activity alongside the company's performance and valuation.
2026-02-11 07:27:20
Mizuho has increased its price target for Envista Holdings Corp. (NYSE:NVST) to $27.00 from $24.00, maintaining a Neutral rating, following the company's better-than-expected 2026 guidance. Envista's stock is currently trading near its 52-week high, boasting a 35.24% year-to-date return. The revised target is based on an increased 2026 and 2027 EPS forecast, with Mizuho anticipating Envista will outgrow the dental market.
2026-02-10 12:29:14
Mizuho has increased its price target for Envista Holdings Corp. to $27 from $24, maintaining a Neutral rating, following the company's strong 2026 guidance that met or exceeded medium-term targets. Envista is also expected to outgrow the dental market in 2026 and has seen upward revisions in its 2026 and 2027 EPS estimates, despite its current high P/E ratio. The stock is considered slightly undervalued by InvestingPro's Fair Value assessment.
